The Clinical Development of Anti-Cancer Drug Candidate BEBT-908 Selected as one of “National Major Scientific and Technological Special Project for “Significant New Drugs Development” in China
  On February 27, Guangzhou BeBetter's BEBT-908 clinical development program was selected as one of the prestigious "National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the 13th Five-year Plan Period". With matching award from Guangzhou City government, the award totaled over 10 million RMB.
   
   The National Major Scientific and Technological Special Project for "Significant New Drugs Development" is oriented by practical application and industrialization development. Its main goals are to support development of a number of drugs to treat China's major diseases, improve the national drug innovation system, enhance the capability of independent innovation, and accelerate the transformation of the country from imitation to innovation.

    BEBT-908 is an HDAC/PI3K dual inhibitor with a first-in-class structure. It can attack and disrupt both HDAC and PI3K signaling pathways simultaneously with extremely high potency.  In preclinical studies, it demonstrated impressive activities against lymphoma, myeloma, and leukemia, causing tumor regression in animal models. BEBT-908 is currently undergoing phase I clinical trial in China.  As the number of newly diagnosed leukemia, myeloma, and chronic lymphocytic leukemia patients annually exceeds 100, 000 in China, BEBT-908 has great potential as an anti-cancer drug.